Welcome to the full-year 2024 Novo Nordisk earnings conference call. [Operator instructions] Please be advised that today's ...

These compounds take a different approach to weight loss than existing medications, which can cause nausea, vomiting and ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current best-selling drug in this area, Wegovy, to shame. Let's look deeper into these ...

A rising number of people have accepted GLP-1s as a way to treat obesity, which affects more than 100 million Americans. © 2024 Fortune Media IP Limited. All Rights ...

Regardless of diabetes status, every 1% of body weight loss was tied to a 3% lower risk of discontinuation ... Saxenda), semaglutide (Ozempic, Wegovy), or tirzepatide (Mounjaro, Zepbound ...

Now, a new study finds that Ozempic, along with similar drugs such as Wegovy, has had a broad “economic and societal impact” because of “noticeable shifts in dietary behavior.” The study ...

More and more people are taking weight loss injectables like Wegovy and Mounjaro — and though the drugs are gaining credibility when used properly, pharmacy experts are worried that not everyone ...

More than half of adults with overweight or obesity prescribed a GLP-1 discontinue their drug within 1 year, with discontinuation ... semaglutide (Ozempic/Wegovy, Novo Nordisk) or tirzepatide ...

More U.S. adults believe it is a good thing than a bad thing for adults to use weight-loss drugs like Ozempic, Wegovy and other brands if they are struggling with obesity or have a health ...

Demand for weight loss jabs continues to surge, particularly as the NHS began offering Wegovy in late 2023 and will start offering Mounjaro to patients in March 2025. They have also become ...

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...